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a b s t r a c t
Progressive Multifocal Leukoencephalopathy (PML) is caused by lytic replication of JC virus (JCV) in
speciﬁc cells of the central nervous system. Like other polyomaviruses, JCV encodes a large T-antigen
helicase needed for replication of the viral DNA. Here, we report the development of a luciferase-based,
quantitative and high-throughput assay of JCV DNA replication in C33A cells, which, unlike the glial cell
lines Hs 683 and U87, accumulate high levels of nuclear T-ag needed for robust replication. Using this
assay, we investigated the requirement for different domains of T-ag, and for speciﬁc sequences within
and ﬂanking the viral origin, in JCV DNA replication. Beyond providing validation of the assay, these
studies revealed an important stimulatory role of the transcription factor NF1 in JCV DNA replication.
Finally, we show that the assay can be used for inhibitor testing, highlighting its value for the
identiﬁcation of antiviral drugs targeting JCV DNA replication.
& 2014 Elsevier Inc. All rights reserved.
Introduction
There are presently 12 known human polyomaviruses (reviewed
in (Ehlers and Wieland, 2013; Scuda et al., 2013)), many of which
have been associated with important diseases (reviewed in (Ferenczy
et al., 2012; Jiang et al., 2009; White et al., 2013)). As a result, there is
increased interest in understanding the life cycles of these viruses
and their tropism for different cells within the human body. Progress
in deciphering the biology of polyomaviruses will help address the
growing need for therapeutic interventions that can limit the
propagation of these infectious agents.
JC virus (JCV) is an example of a pathogenic human polyomavirus
(reviewed in (Jiang et al., 2009; Padgett and Walker, 1973; Shishido-
Hara, 2010)). JCV infects 50–80% of the human population (Knowles
et al., 2003; Padgett and Walker, 1973) and is generally asymptomatic.
However, its reactivation in immuno-compromised individuals can
lead to the development of Progressive Multifocal Leukoencephalo-
pathy (PML), an often-fatal demyelinating disease (reviewed in
(Bellizzi et al., 2013; Brew et al., 2010; Ferenczy et al., 2012)). Examples
of susceptible individuals are those suffering from AIDS or patients
undergoing immunosuppressive therapy, such as organ transplant
recipients or multiple sclerosis patients treated with the monoclonal
antibody Tysabri (reviewed in (Ferenczy et al., 2012; Koralnik, 2013)).
PML results from the ability of JCV to infect cells of the central nervous
system and in particular glial cells (reviewed in (Major et al., 1992)),
although some recent reports indicate that it may also infect neurons
(e.g., (DuPasquier et al., 2003; Wuthrich et al., 2009)).
A central event during the life cycle of all polyomaviruses is
replication of their viral DNA genome. The prototypic primate
polyomavirus, simian virus 40 (SV40), has long been used as
a paradigm to investigate the mechanisms employed during viral
DNA replication (reviewed in (Fanning and Zhao, 2009; Meinke and
Bullock, 2012)). As with all polyomaviruses, replication of the SV40
genome is dependent on a viral protein, termed large T antigen
(T-ag); the other factors needed for this process being supplied by
the infected cell (reviewed in (Bell and Dutta, 2002; Fanning and
Knippers, 1992; Hurwitz et al., 1990; Kelly, 1988)). T-antigen
contains several functional regions, including the N-terminal
J-domain, the origin binding domain (OBD) and the helicase domain
(An et al., 2012; Simmons, 2000; Topalis et al., 2013). Upon binding
to the viral origin, T-ag engages in multiple protein/origin and
protein/protein interactions (reviewed in (Borowiec et al., 1990;
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Bullock, 1997; Fanning and Knippers, 1992)). Critical insights into
these fundamental processes were provided by recent structural
studies of SV40 T-ag (reviewed in (Meinke and Bullock, 2012)).
For example, studies addressing how the OBD interacts with
DNA revealed how a region spanning the A1 & B2 loops binds
site-speciﬁcally to the central region of the viral origin (Bochkareva
et al., 2006; Chang et al., 2013; Meinke et al., 2007). Similarly,
structural and functional studies of the helicase domain led to a
number of fundamental observations, such as helping to reveal how
ssDNA is pumped through the central channel of the helicase
domain (Gai et al., 2004; Li et al., 2003). They have also provided
critical insights into the oligomerization process (Gai et al., 2004; Li
et al., 2003).
The ﬁrst structural study of JCV T-ag was recently reported
(Meinke et al., 2014). Remarkably, it established that differences
exist between the T-ag OBDs encoded by JCV and SV40. Of
particular interest was the discovery that the JCV OBD contains a
relatively large C-terminal pocket that is bound by residues from
the A1 and B2 loops of an adjacent OBD (Meinke et al., 2014). This
and other observations led to the conclusion that the T-ag's
encoded by SV40 and JCV, despite being highly homologous, bear
subtle but important differences.
To help establish JCV DNA replication as a valid antiviral target
for the treatment of PML, we have set out to extend our initial
structural studies of JCV T-ag to provide a broader understanding
of the regions of the molecule responsible for binding to DNA and
interacting with cellular replication proteins. In addition, we have
initiated investigation of the regulatory mechanisms that govern
replication of the JCV genome in different cell types, as they may
also provide opportunities for antiviral drug discovery. With these
goals in mind, we elected to establish a T-ag dependent high-
throughput assay for JCV DNA replication. The assay described
herein should greatly facilitate the study of JCV DNA replication
and the screening for inhibitors of this process.
Results
Development of a luciferase based assay for JCV DNA replication
We previously described cellular assays of SV40 and HPV31 DNA
replication based on a dual-luciferase readout (Fradet-Turcotte et al.,
2010). Here, we tested if this methodology could be applied to the
study of JCV DNA replication. In our initial series of experiments, we
aimed to construct the necessary T-ag and origin-containing plasmids
needed for this assay and to identify cell lines capable of supporting
robust levels of JCV DNA replication. An illustration of the luciferase
based JCV replication assay is presented in Fig. 1A. In overview, a
plasmid encoding JCV T-ag is co-transfected into permissive cells
along with a second plasmid containing both the JCV origin of
replication and the ﬁreﬂy luciferase reporter gene. As a control, a
third plasmid encoding Renilla luciferase is included in the transfec-
tion. After suitable time intervals, the amount of T-ag dependent
replication is determined by measuring the levels of ﬁreﬂy luciferase
activity expressed from the ori-containing plasmid, using a lumin-
ometer (Fradet-Turcotte et al., 2010). The levels of Renilla luciferase
activity measured in the same cells are also determined and used for
normalization.
To fully introduce this assay, it is also necessary to provide
a brief description of the viral regulatory region. In the JCV
genome, a region termed the non-coding control region (NCCR)
contains the viral origin of replication and it separates the early
and late genes (reviewed in (Bellizzi et al., 2013; Ferenczy et al.,
2012)). The hyper-variable promoter/enhancer region within the
NCCR is of particular interest because it is a signiﬁcant modulator
of JCV activity (e.g.,(Ault, 1997; Feigenbaum et al., 1992; Jensen and
Major, 2001; Johnson et al., 2013)). In JCV isolates from the urine of
healthy individuals, the single promoter/enhancer region is highly
conserved (e.g., (Agostini et al., 1996; Jensen and Major, 2001;
Yogo et al., 1990)) and is termed the archetype. Upon immuno-
suppression and reactivation of the virus, rearrangements within
the hyper-variable region occur (reviewed in (Jensen and Major,
2001; Koralnik, 2013; White et al., 2009)) that correlate with viral
spread and development of PML. As a result, patients with poor
clinical outcomes have a high proportion of tandem repeats and
insertions in the enhancer sequences (e.g. (Ault, 1997; Pﬁster et al.,
2001; Vaz et al., 2000). It is thought that such changes in the
hyper-variable enhancer affect levels of viral transcription and
replication which in turn, govern JCV cellular tropism (e.g., (Ault,
1997; Feigenbaum et al., 1987)). However, the exact mechanism(s)
by which the enhancer/promoter regions stimulate JCV replication
has not been fully established. A depiction of the Mad-1 derived
tandem duplication present in pFL-JCVori-TD, the pFL-JCVori deriva-
tive used in our initial studies, is presented in Fig. 1B (note, the
enhancers are subdivided into sections a–f (Jensen and Major, 2001);
reviewed in (Ferenczy et al., 2012)).
Identifying a suitable cellular host for characterization of JCV DNA
replication
In initial studies, we selected several cell lines to test for JCV
DNA replication. Given the tropism of JCV for glial cells, we tested
Fig. 1. Diagrams of the luciferase based JCV replication assay and the Mad-1 NCCR. A. On the left are depictions of three plasmid types used in the assay. They include
a plasmid encoding JCV T-ag (pJCVT-ag), a plasmid containing both the JCV origin of replication and the ﬁreﬂy Fluc gene (pFL-JCVori) and a plasmid encoding Renilla
luciferase (pRL). These plasmids are transfected into human cell lines where T-ag dependent replication takes place. Following an adequate time (e.g., 48 or 72 h) the amount
of light released by the ﬁreﬂy and renilla luciferases is measured using a luminometer. B. A diagram of the tandemly duplicated regulatory sequences adjacent to the JCV
origin of replication in the Mad-1 strain (Frisque, 1983). Individual regions within the NCCR are indicated; they include the core origin (containing the central Site II region
and ﬂanking early palindrome (EP) and TATA regions), Site I and subdomains within the enhancers.
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the human glioma cell line Hs 683 and the human primary
glioblastoma cell line U87. The Hs 683 and U87 cells were of
particular interest because they have been used in a number of
previous studies of JCV DNA replication (e.g., (Ault, 1997; Bollag
et al., 2010; Chang et al., 1996; Chang et al., 1994; Gosert et al., 2010)).
The cervical carcinoma cell line C33A was also included for historical
reasons, as it was the cell line used to implement our previous SV40
and HPV31 DNA replication assays (Fradet-Turcotte et al., 2010).
Results from representative assays, designed to measure levels
of JCV replication in different cell types and conducted with the
tandem duplication containing pFL-JCVori-TD plasmid, are pre-
sented in Fig. 2A. Inspection of this ﬁgure establishes that reac-
tions conducted with C33A cells had robust levels of replication. In
contrast, the identical reagents did not support JCV DNA replica-
tion in Hs 683 cells (as negative controls, the reactions presented
in columns 1 and 3 were performed in the absence of T-ag).
Importantly, the failure to detect replication in Hs 683 cells was
not due to problems related to transfection efﬁciencies as similar
levels of Renilla luciferase were detected in C33A and Hs 683 cells
(Fig. 2B. In other assays, the levels were equal (data not shown)).
To compare the expression levels of JCV T-ag in C33A and Hs 683
cells, Western blots were performed. Inspection of Fig. 2C estab-
lishes that while JCV T-ag is readily detected in C33A cells, T-ag is
present in Hs 683 cells only at very low levels. Selective proteo-
somal degradation of T-ag in Hs 683 cells is unlikely since no
changes in T-ag levels were detected upon treatment of cells with
MG132 at concentrations as high as 0.32 mM (data not shown).
Finally, in a similar series of experiments, we also failed to detect
JCV DNA replication in U87 cells (data not shown).
JCV T-ag fails to accumulate in the nuclei of Hs 683 and U87 cells
The localization of T-ag to the nuclei of cells is essential for
polyomavirus DNA replication (reviewed (An et al., 2012; Borowiec
et al., 1990; Topalis et al., 2013)). Therefore, we investigated, via
immunoﬂuorescence microscopy ((Boichuk et al., 2010) and refer-
ences therein), the localization of JCV T-ag in C33A cells, as well as
in the glioma cell lines Hs 683 and U87. Inspection of Fig. 3A (rows
2–4, and the accompanying bar graphs) establishes that in
replication competent C33A cells, JCV T-ag is generally found
within the nucleus. This was true of nearly 75% of the T-ag positive
cells examined. In contrast, in Hs 683 cells, JCV T-ag is largely
excluded from the nuclei ((Fig. 3B, rows 2–4); only 7% of Hs 683
cells had T-ag in their nuclei; most of the cells (89%) had T-ag in
the cytoplasm). Furthermore, the same distribution of T-ag was
seen when these experiments were performed with vectors
encoding additional viral factors (e.g., small t antigen (Bollag
et al., 2010) and the entire Mad-1 genome (Dang et al., 2012):
(data not shown)). Therefore, it is concluded that the failure to see
JCV T-ag in the nuclei of glioma cells is not due to the absence of
essential viral factors (e.g., the T' proteins (Frisque, 2001; Prins and
Frisque, 2001) or agnoprotein (Akan et al., 2006; Khalili et al.,
2005; Okada et al., 2001; Safak et al., 2001; Saribas et al., 2012)).
An additional set of immunoﬂuorescence experiments was
conducted using a method designed to “pre-extract” unbound
T-ag from within the cell (Mirzoeva and Petrini, 2001). This
method was employed in order to better visualize the distribution
of JCV T-ag within the nuclei of these cells. Fig. 3C presents
representative images that depict the distribution of T-ag in the
nuclei of C33A, Hs 683 and U87 cells (images of the latter two cell
types were derived from the minor population of cells with T-ag in
the nuclei). Inspection of Fig. 3C (top line) provides additional
evidence that in C33A cells, JCV T-ag is in the nuclei where it
clusters in discrete foci. An analogous punctate distribution of T-ag
in the nuclei of replication competent cells was seen in previous
studies of SV40 DNA Zhao et al., 2008 and JCV replication
((Gasparovic et al., 2009; Orba et al., 2010; Shishido-Hara et al.,
2008); reviewed in (Shishido-Hara, 2010)). Inspection of Fig. 3C
(middle and bottom rows) establishes that a similar punctate
distribution of JCV T-ag occurs in the Hs 683 and U87 cells. The
signiﬁcance of this distribution of JCV T-ag in the nuclei of cells
will require additional studies. Nevertheless, the general absence
of T-ag from the nuclei of glial derived cells lines, and relatively
low levels of T-ag expression, are obvious reasons why these
glioma cells fail to support JCV DNA replication. In contrast, it is
apparent that C33A cells appear very promising for subsequent
studies of JCV DNA replication. Therefore, we elected to further
validate the replication assay in C33A cells.
Validation of the JCV DNA replication assay conducted in C33A cells
Time- and origin-dependence of the assay
The time- and origin-dependence of the assay were tested
using a number of different NCCR conﬁgurations with similar
results; for simplicity, only those obtained with the pFL-JCVori
plasmid that contains the “archetype” single enhancer are pre-
sented in Figs. 4 and 5. Inspection of the left side of the graph
presented in Fig. 4A establishes that in the presence of a plasmid
containing the JCV origin of replication (Oriþ), there is a time
dependent increase in luciferase signal. Moreover, it is apparent
from the right side of the ﬁgure that this increase in luciferase
signal does not occur when the assay is conducted with a plasmid
lacking the JCV origin (Ori). Given the importance of T-ag to viral
replication, a Western blot was used to monitor the levels of T-ag
expression (Fig. 4B). It is apparent that T-ag is stably expressed in
these cells and that the failure to detect replication of JCV DNA in
the Ori reactions is not due to aberrant T-ag levels.
Further validation of JCV DNA replication via qPCR
To test whether the increase in luciferase activity was the result
of a higher copy number of DNA, we used qPCR to directly
measure the amount of Fluc containing plasmid DNA ( see section
‘Materials and methods’). The qPCR reactions in Fig. 4C, columns
1–3, all contained genomic DNA extracted from C33A cells following
Fig. 2. Examples of representative assays establishing that JCV DNA replication
takes place in only certain cell lines. A. Results of JCV DNA replication assays
conducted in the cervical carcinoma cell line C33A (left two columns) and the
glioma cell line Hs 683 (right two columns). B. A plot of the Renilla luciferase levels
in the “- T-ag” controls presented in Fig. 2A. C. A Western blot showing the relative
levels of T-ag present in equal aliquots (10 μg protein) of whole cell extracts from
C33A and Hs 683 cells. As a loading control, Vinculin levels were also determined.
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transfection with the indicated plasmids. Inspection of column 1
demonstrates that in the absence of the plasmid encoding JCV
T-ag (i.e., pCMV-JCVT-ag), the primers speciﬁc for the ﬁreﬂy
luciferase gene ampliﬁed very little DNA. In contrast, in the
presence of JCV T-ag and the origin containing pFL-JCVori plasmid
(column 2), there is a marked increase in the amount of luciferase
encoding DNA that is ampliﬁed. Finally, it is apparent from the data
presented in column 3, the product of a reaction conducted with
pCMV-JCVT-ag and pFL (the plasmid that lacks the JCV origin) that
replication is dependent on the JCV origin of replication.
Using mutant T-ag's to further validate the assay and for initial
structure function studies
Previous SV40 based studies identiﬁed a number of residues in
T-ag that are essential for viral DNA replication. For example, they
established that residues in the A1 and B2 loops are critical for
DNA binding (e.g., (Luo et al., 1996; Simmons et al., 1990; Simmons
et al., 1990)). They also revealed that residues in the helicase
domain at the tip of the “beta hairpin” are needed for melting of
the origin (Kumar et al., 2007; Reese et al., 2004; Shen et al., 2005)
and for interactions with the sugar-phosphate backbone of ssDNA
(Gai et al., 2004). Therefore, given the extensive homology
between SV40 and JCV T-ag's, mutations at the corresponding
residues in JCV T-ag should, in principle, inactivate the C33A based
JCV DNA replication assay.
The relative locations of the residues in the JCV T-ag OBD and
helicase domains that were selected for mutation are indicated in
Fig. 5A. Structural models of the JCV OBD (Meinke et al., 2014) and
helicase domains (see section ‘Materials and methods’) are pre-
sented in Fig. 5-B.1 and B.2. Regarding mutations in the OBD
(Fig. 5B.1), the locations of R155 and H204, situated in the A1 and
B2 loops, respectively, are shown on the surface of the molecule.
Within the JCV T-ag helicase domain (Fig. 5B.2), the location of
a residue at the tip of the beta-hairpin (i.e., H514) is shown. Also
presented is the location of a residue (i.e., R499) that was
predicted, based on studies of SV40 T-ag (Gai et al., 2004; Li
et al., 2003), to play a critical role in ATP binding. Finally,
phosphorylation of JCV T-ag residue Thr 125 has been demon-
strated to be essential for the replication of JC virus ((Swenson
et al., 1996; Tyagarajan and Frisque, 2006). Unfortunately, a
structure does not exist for this region of any polyomavirus T-ag).
Fig. 3. Determination, via immunoﬂuorescence, of the subcellular localization of JCV T-ag in C33A cells and two glial cell lines (Hs 683 and U87). A. Representative images of
JCV T-ag (green) within C33A cells obtained using the previously described “standard” technique (Boichuk et al., 2010). The cell nuclei were stained with DAPI. The
histograms present the percentage distribution of T-ag in the nuclei, both nuclei and cytoplasm or just cytoplasm of the two different cell types. B. Representative images of
JCV T-ag within Hs 683 cells using the identical technique; the cell nuclei are indicated. (In both instances, the percentages were established after counting300 cells).
C. Demonstration, using a modiﬁcation of the immunoﬂuorescence technique that involves pre-extraction of T-ag, of the “punctate distribution” of JCV T-ag in the nuclei of
C33A, Hs 683 and U87 cells.
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Inspection of Fig. 5C establishes that JCV T-ag molecules,
containing alanine substitutions at the predicted “essential” resi-
dues, were all unable to support JCV DNA replication (four
columns on the right). Moreover, the failure of these mutant
T-ag molecules to increase the levels of ﬁreﬂy luciferase activity
provides further validation that this readout provides an accurate
measure of ori-plasmid replication or, stated otherwise, that the
signal obtained with wt T-ag (second column) reﬂects replication
of the viral DNA and not other processes (e.g., transactivation of
the luciferase gene). In addition, inspection of the Western blot
presented in Fig. 5D establishes that the failure of the individual
Fig. 4. A time course of JCV DNA replication conducted in C33A cells. A. The
replication reactions on the left were conducted with the single enhancer contain-
ing pFL-JCVori plasmid; those on the right were conducted with pFL; a derivative of
pFL-JCVori lacking the JCV ori. The times at which the assays were conducted are
indicated, as are the Fluc/Rluc ratios for the indicated reactions. B. Results of a
Western blot used to determine the amount of JCV T-ag present in C33A cells
following the indicated amounts of time. As a loading control, Vinculin levels were
also determined. C. Levels of JCV replication measured via quantitative real-time
PCR (qPCR). Column 1 presents the results of a reaction conducted in the presence
of pFL-JCVori, but in the absence of the plasmid encoding JCV T-ag (-T-ag). Column
2 presents the results of a reaction conducted in the presence of plasmids
containing both the JCV origin and T-ag (þT-ag). The third column presents the
results of a reaction conducted only in the presence of plasmid encoding T-ag
(Ori).
Fig. 5. JCV DNA replication assays conducted with mutant forms of T-ag. A. A linear
depiction of JCV large T-ag showing its major domains (i.e., J, OBD, ATPase/helicase
and host range (HR)). The relative locations of the T-ag residues that were
mutated to alanines (see section ‘Materials and methods’) are indicated on the
top of the ﬁgure. B1. A surface representation of the JCV OBD (Meinke et al., 2014)
showing the relative position of R155 and H204 (shown in red). B2. A surface
representation of the JCV helicase domain, prepared using the program Phyre 2
(Kelley and Sternberg, 2009). This model shows the location of a residue at the base
of the beta-hairpin (H514) and a residue that, based on studies of SV40 T-ag
(Li et al., 2003), is likely involved in ATP binding (R499). C. JCV replication assays
conducted in C33A cells for 72 h. with T-ag molecules containing mutations at
residues that are predicted to be essential for DNA replication. The extreme
left column presents the result of a replication reaction conducted in the absence
of T-ag, while the amount of replication obtained with wt JCV T-ag is shown
in the second column. The following four columns present the amount of
replication obtained with the T125A, R155A, R499A and H514A mutants. D. Results
from a Western blot demonstrating that levels of “mutant T-ag” are not different
from those of wt JCV T-ag. As a loading control, levels of Vinculin were also
determined.
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T-ag mutant proteins to support replication is not due to changes
in their levels of expression. (It is noted that the H204A T-ag
mutation was also constructed and its ability to support DNA
replication analyzed; however, much lower protein levels were
associated with this mutant (data not shown). Therefore, replica-
tion data obtained with this mutant T-ag are not presented).
Systematic characterization of the JCV regulatory sequences in terms
of their contributions to viral DNA replication
Having validated the JCV DNA replication assay in C33A cells, it
was of interest to conduct a systematic analysis of the origin
sequences needed for this process. Initially, we determined the
extent to which the enhancer sequences modulate the levels of
DNA replication within C33A cells. The DNA constructs containing
different derivatives of the “archetype” NCCR used in this study,
are presented in Fig. 6A. The single Mad 1 derived 98 bp enhancer
(Frisque, 1983) present in pFL-JCVori, the construct used in certain
previous replication assays (i.e., Figs. 4,5), is presented on line 1.
Variants of this construct, in which the enhancer sequences were
deleted, include one in which all of sub-region e and part of c were
deleted ((18 bp and 31 bp, respectively; this represents51% of
the enhancer). The plasmid containing this truncation was termed
pFL-JCVoriΔ1/2 enh; the NCCR is depicted on line 2. In a second
variant, the entire enhancer was deleted; the plasmid containing
this derivative was termed pFL-JCVoriΔenh and the NCCR is
presented on line 3. Finally, the Mad 1 strain has a tandem
duplication of the enhancer sequences, as well as the addition of
the F sub-region (Frisque et al., 1984). Therefore, as previously
noted, the Mad 1 sequences were engineered into an additional
derivative of the pFL-JCVori plasmid that was termed pFL-JCVori-
TD (a depiction of the NCCR in this plasmid is shown in Fig. 1B).
Levels of replication obtained by different promoter/enhancer
elements
The data presented in Fig. 6B compare the relative levels of JCV
DNA replication supported by plasmids containing different
enhancer elements (i.e., those presented in Fig. 6A and Fig. 1B.
Note, in Fig. 6B plasmids pFL-JCVori, pFL-JCVoriΔ1/2 enh, pFL-
JCVoriΔenh and pFL-JCVori-TD are abbreviated Enh-core-I, Δ1/2
Enh-core-I, ΔEnh-core-I and 2XEnh-core-I, respectively. Further-
more, the pFL plasmid, lacking the JCV ori, was abbreviated as
(Δ ori)). As expected, no replication was detected with the ori
minus control plasmid (Δ ori) at either 48 or 72 h post transfec-
tion (left two columns). Of interest, the presence of the second
enhancer did not increase JCV DNA replication (compare the levels
of replication supported by the single enhancer (enh-core-I)
versus the two enhancer (2X-enh-core-I) constructs). Therefore,
the previously reported tandem duplication dependent stimula-
tion of JCV transcription/replication in glial cells (e.g., (Jensen and
Major, 2001; Pﬁster et al., 2001; Vaz et al., 2000); reviewed in
(Gheuens et al., 2012)) is not a feature of JCV DNA replication in
C33A cells. The extent to which sequences within the single 98-bp
enhancer (i.e., the archetype) contribute to JCV replication was
also addressed. The results of these studies reveal that relative to
the single enhancer containing plasmid (Fig. 6A; line 2), plasmid
Δ1/2 enh (Fig. 6A; line 3) had nearly an equivalent amount of
replication activity (compare columns labeled enh-core-I with
those labeled Δ1/2 enh-core-I). However, replication was greatly
reduced by the complete removal of the remaining enhancer
sequences (last pair of columns labeled Δenh-core-I).
Evidence that NF-1 family members are needed for JCV DNA
replication in C33A cells
The experiments presented in Fig. 6B established that the level
of JCV DNA replication obtained with the partial enhancer (Δ1/2
enh-core-I) was nearly the same as with the entire enhancer. In
contrast, very little replication was detected upon the complete
removal of the enhancer (Δenh-core-I; last pair of histograms).
This is an interesting observation given that the NF-1A binding site
(Amemiya et al., 1989) in sub-region c (reviewed in (Ferenczy
et al., 2012)) is intact in the partial, but not in the full, deletion.
Given that NF-1 family members have been previously implicated
in JCV replication (Amemiya et al., 1992; Monaco et al., 2001;
Ravichandran and Major, 2008; Sock et al., 1991), it was of interest
to test whether the NF-1A binding site is required for JCV
replication in the C33A based system. Therefore, the NF-1A
binding site (Amemiya et al., 1989) in the NCCR derivatives
presented in Fig. 7A were mutated (see section ‘Materials and
methods’) and the plasmids containing these mutations were used
in additional JCV replication assays. Inspection of Fig. 7B estab-
lishes that relative to the parental sequences in which the NF-1A
site was intact, derivatives containing the mutation at the NF-1A
binding site had reduced levels of JCV DNA replication (compare
shaded columns to striped columns). As previously noted, the
luciferase based JCV replication assay expresses T-ag from a
separate plasmid. Therefore, the results presented in Fig. 7B
indicated that NF-1 family members directly promote JCV DNA
Fig. 6. Determining the extent to which the enhancer/promoter regions stimulate
JCV DNA replication. A. Alternative forms of the enhancer/promoter region
analyzed in these studies. The monomeric enhancer present in plasmid pFL-JCVori
is presented on the ﬁrst line (abbreviated “enh-core-I”). The 98 bp enhancer is sub-
divided into subregions e, c and a (the TATA region includes subregion a). Removal
of approximately half of the enhancer created the partial enhancer deletion (line 2;
abbreviated “Δ1/2enh-core-I”). Removal of the entire enhancer created the enhan-
cer deletion (line 3; abbreviated “Δenh-core-I”). B. The levels of JCV DNA replication
supported by plasmids containing the different conﬁgurations of the NCCR
depicted in Fig. 6A, and Fig. 1B, after 48 and 72 h. As a control, the ﬁrst two
columns depict the amount of DNA replication obtained with pFL, the construct
lacking the JCV origin. The levels of replication obtained after 48 and 72 h, with the
standard pFL-JCVori plasmid containing a single enhancer (Fig. 6A, line 1), and the
duplicated enhancer found in the Mad-1 strain (Fig. 1B) are shown in the following
four columns. Also shown are the relative levels of replication obtained with
truncated forms of the single enhancer (i.e., the “Δ1/2 enh” (Fig. 6A; line 2) and the
“Δenh” conﬁgurations (Fig. 6A; line 3)).
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replication in C33A cells, rather than playing an indirect role via
up-regulating the expression of T-ag.
Is Site I required for JCV replication in C33A cells?
The Site I region of the SV40 origin is required for viral DNA
replication in vivo ((Guo et al., 1991) and references therein).
Likewise, it has been reported that the Site I region of the JCV
origin stimulates replication in the U138 glial cell line (Sock et al.,
1993). To determine if Site I stimulates JCV DNA replication in the
C33A based luciferase assay, additional derivatives of the NCCR in
plasmid pFL-JCVori were made (Fig. 8A). In one, the sequences
encompassing the “late side” enhancer were kept intact and only
Site I deleted (line 1; the NCCR in this derivative is abbreviated
“enh-core-ΔI”). In the second construct, both Site I and the
enhancer sequences are deleted; as a result, this pFL-JCVori
derivative contained just the JCV core origin (line 2; the NCCR in
this construct was abbreviated “Δenh-core-ΔI”).
The plasmids containing these deletions are then used in
additional JCV DNA replication assays (Fig. 8B). Inspection of this
ﬁgure reveals that both plasmids containing Site I deletions were
signiﬁcantly reduced in terms of their ability to support JCV DNA
replication. (Compare the data obtained with the positive control
(i.e., pFL-JCVori, abbreviated as enh-core-I) to the data obtained
with plasmids containing deletions in Site I (i.e., enh-core-ΔI and
Δenh-core-ΔI)). Control reactions, conducted with plasmids lack-
ing the JCV origin, are presented in the left two columns).
Collectively, these assays establish that Site I is required for the
replication of JCV DNA in C33A cells.
Establishing the pentanucleotide requirements for JCV DNA
replication
All four pentanucleotides in the SV40 core origin are needed for
DNA replication (Dean et al., 1987; Joo et al., 1998). In contrast, it
has been reported that only three pentanucleotides in the analo-
gous “core origin” region are needed for the replication of murine
polyomavirus (Harrison et al., 2013) and Merkel cell polyomavirus
(Harrison et al., 2011). Thus, the literature contains differences in
terms of the pentanucleotide requirements for polyomavirus DNA
replication. Therefore, we elected to determine if all four penta-
nucleotides in the JCV core origin are required for the replication
of JCV DNA in C33A cells.
A diagram of the sequences comprising the JCV core origin of
replication is presented in Fig. 9A. As illustrated by the two pairs of
sequences above and below the central sequence, four derivatives
of the pFL-JCVori plasmid were constructed in which transition
mutations replaced the individual pentanucleotides in the core
origin. These plasmids were then used in an additional series of JCV
replication assays (Fig. 9B). As a negative control, replication
reactions were conducted with plasmid pFL (Ori; containing the
ﬂuc gene but lacking the JCV origin (column 1)). As a positive
control, a reaction was conducted with the pFL-JCVori plasmid
(column 2). As expected, there was no detectable signal with the
negative control, but clear evidence for replication with plasmid
pFL-JCVori (compare columns 1 and 2). The results obtained in
reactions conducted with plasmids containing transition mutations
in P1, P2, P3 and P4 are shown in the following four columns. It is
apparent that none of the mutated origins supported replication.
The JCV replication assay can be used to screen for inhibitors of DNA
replication
The studies presented above provided evidence that the
luciferase-based assay faithfully recapitulates many of the known
features of JCV DNA replication. This, coupled with the high-
throughput and quantitative nature of the dual-luciferase readout,
makes this assay an attractive one for the screening of small
molecule inhibitors of JCV DNA replication and/or of human DNA
replication. To assess the potential of this assay for compound
screening, we ﬁrst determined that the C33A cells could tolerate
up to 0.5% DMSO (data not shown) and then tested the effect of
three well-characterized DNA replication inhibitors: aphidicolin,
hydroxyurea and gemcitabine. The results presented in Fig. 10
demonstrate that the luciferase signal could be reduced, in a dose
dependent manner, by all three compounds. Furthermore, their
measured EC50 values in the JCV assay are in good agreement with
those obtained in our related SV40 assay (data not shown).
An advantage of the dual luciferase readout is that the Renilla
luciferase internal control can be used to identify compounds that
are toxic or inhibit viral DNA replication by an undesired mechanism.
In the case of aphidicolin, hydroxyurea and gemcitabine, neither one
of them decreased the Renilla luciferase levels by more than 20% at
the highest concentration tested (10 mM, 10 mM and 2 mM, respec-
tively), thus attesting to their speciﬁcity. Collectively, these results
highlight the potential of this assay for future screening of small-
molecule libraries for inhibitors of JCV DNA replication. Finally, since
at high concentrations the replication inhibitors greatly reduce levels
of JCV DNA replication (Fig. 10), these studies further establish that the
luciferase signal is largely dependent on replication of the ori-
containing plasmid.
Discussion
Using the cervical carcinoma line C33A, we have developed a
quantitative and versatile luciferase based HTS assay for studying
Fig. 7. Determining the levels of JCV DNA replication supported by plasmids
containing mutations within the NF-1A binding sites. A. The locations (in red) of
the NF-1A binding site within the archetype (line 1) and “Δ1/2enhancer” (line 2)
enhancer sequences (Frisque et al., 1984). B. The relative levels of JCV DNA
replication obtained at 48 and 72 h with the parental pFL-JCVori and pFL-JCVori
(Δ1/2enhancer) plasmids and the derivatives containing mutations in the NF-1A
binding sites (Fig. 7A).
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JCV DNA replication. The two virally encoded factors that are
essential for DNA replication in this cell line are T-ag and the origin
containing NCCR region. Previous studies, including those employ-
ing a cell free replication assay (Nesper et al., 1997), also led to the
conclusion that JCV large T-ag is the only viral protein required to
mediate the replication of an origin containing plasmid.
The reason(s) why C33A cells are so efﬁcient at supporting JCV
DNA replication has yet to be determined. Perhaps relevant to this
issue, it was previously established that the accumulation of
SV40 T-ag in nuclear foci is essential for viral replication (Tang
et al., 2000; Zhao et al., 2008). Therefore, one reason why C33A
cells may be efﬁcient at supporting JCV DNA replication is that JCV
T-ag accumulates in analogous nuclear foci. This ﬁnding may
indicate that in C33A cells, ND10 domains are involved in
JCV replication; a possibility supported by previous studies
((Gasparovic et al., 2009; Shishido-Hara et al., 2008); reviewed
in (Shishido-Hara, 2010)). However, it should be noted that C33A
cells do not contain papillomavirus DNA (Yee et al., 1985); there-
fore, papillomavirus encoded proteins are not involved in estab-
lishing the favorable conditions for JCV DNA replication.
Prior studies have also identiﬁed a number of proteins that
bind to the JCV enhancer and promoter regions (reviewed in
(Bellizzi et al., 2013; Ferenczy et al., 2012)). Therefore, a related
issue is whether C33A cells are enriched in particular cellular
proteins that bind to sequences within the NCCR and stimulate JCV
replication. Regarding speciﬁc protein candidates, several reports
indicate that the binding of NF-1 family members to the NF-1
binding sites stimulates viral replication (Amemiya et al., 1989;
Marshall et al., 2010; Monaco et al., 2001; Ravichandran et al.,
2006; Sock et al., 1993). Furthermore, it has been suggested that a
particular NF-1 family member (i.e., NF1-X) is a molecular deter-
minant of JCV susceptibility that functions throughout viral
pathogenesis (Messam et al., 2003). Indeed, it has been reported
that overexpression of NF1-X is sufﬁcient to cause nonproductive
cells to become permissive for JCV replication (Messam et al.,
2003). Therefore, it is noteworthy that mutation of the NF-1A
binding site reduces JCV DNA replication in C33A cells. It is
stressed that since T-ag expression is dependent on regulatory
sequences on a second plasmid, the stimulation observed by the
presence of the NF-1 binding site has to reﬂect direct promotion of
JCV DNA replication. The binding of NF-1 family members to NF-1
binding sites is also known to play a role in BKV DNA replication,
but only in the presence of competitor templates (Liang et al.,
2011). Thus, the C33A based luciferase assay, in which direct
stimulation is observed, will be useful for subsequent studies
designed to establish how JCV DNA replication is promoted by
the binding of NF-1 family members. This assay might also play an
important role in the identiﬁcation of additional enhancer binding
cellular factors needed for JCV DNA replication.
Our studies also establish that the Site I region of the JCV origin
is essential for DNA replication in C33A cells, a ﬁnding consistent
with previous observations (Sock et al., 1993). The Site I region of
the SV40 origin is also necessary for DNA replication in vivo ((Guo
et al., 1991) and references therein), but not in vitro (Bullock et al.,
1997). These observations suggest that cellular factors, such as
histones or other chromatin components may play important roles
in the Site I dependent regulation of DNA replication. However, the
precise role played by Site I in polyomavirus DNA replication has
yet to be established.
It has been recently reported that the replication of certain
polyomaviruses is dependent upon only a subset of the pentanu-
cleotides found in Site II (Harrison et al., 2011, 2013). Therefore,
the C33A based replication systemwas also used to investigate the
pentanucleotide requirements for JCV DNA replication. The results
presented herein establish, however, that all four pentanucleotides
in the JCV core origin are needed for replication. Likewise, it was
previously concluded that all four pentanucleotides in the Site II
region of the SV40 core origin are needed for DNA replication
(Dean et al., 1987; Joo et al., 1998). Collectively, these results
suggest that within the polyomavirus family, there are signiﬁcant
differences in the pentanucleotide requirements for replication.
Whether these ﬁndings reﬂect a fundamental difference in the
mechanism(s) utilized during the initiation of viral DNA replica-
tion will require additional studies.
Replication of JC virus is, in general, limited to human cells of
macroglial origin within the CNS (Ferenczy et al., 2012). The
limited host range is largely a function of the NCCR region, which
as previously discussed, is regulated by diverse transcription and
replication factors (reviewed in (Bellizzi et al., 2013; Ferenczy
et al., 2013)). Therefore, it is of interest that the reagents that
support DNA replication in C33A cells do not support JCV DNA
replication in established glioma cell lines (e.g., Hs 683 and U87).
The reason(s) why these glioma cell lines fail to support JCV DNA
replication is not understood. However, our Western blot experi-
ments demonstrate that relative to C33A cells, JCV T-ag accumu-
lates at relatively low levels in Hs 683 and U87 cells. Moreover, our
immunoﬂuorescence studies have established that JCV T-ag accu-
mulates in only a small percentage of the glial cell nuclei. These
limitations in terms of the amounts and cellular distribution of JCV
T-ag may reﬂect that there are cellular based restrictions (e.g.
Windl and Dorries (1995)) on JCV replication in the glioma cells
used herein. The identity of the missing cellular factor(s) is
unclear; however, they may include regulatory proteins such as
NF2 (Beltrami et al., 2013), p53 (Staib et al., 1996) or cyclins A and
B (Radhakrishnan et al., 2003). In addition, low levels of JCV T-ag in
glial cells may reﬂect autophagy (Sariyer et al., 2012), interactions
Fig. 8. Measuring the levels of JCV DNA replication obtained with plasmids having
deletions of Site I. A. Depictions of the NCCR regions in the wild-type “enh-core-I”
derivative containing a deletion in Site I (termed “enh-core-ΔI”; Fig. 8A; line1) and
in a second plasmid in which both the enhancer and Site I were deleted (the core
origin derivative that was termed “Δenh-core-ΔI”; Fig. 8A; line 2). B. The relative
levels of JCV DNA replication obtained at 48 and 72 h with the plasmids containing
deletions in Site I and a wild type control (i.e., Enh-Core-I).
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with the cellular degradation complex SCFβTrCP1/2 (Reviriego-
Mendoza and Frisque, 2011) or metabolic changes, such as glucose
deprivation (Noch et al., 2012).
Curiously, while JCV T-ag was absent from the nuclei of
approximately 90% of the Hs 683 or U87 cells, it was present in
7% of the cells. Why this distribution exists within the glioma
cell population is also unknown. Detecting JCV DNA replication in
Hs 683 and U87 cells will likely depend upon increasing the
percentage of glioma cells that have JCV T-ag in their nuclei
(Broekema and Imperiale, 2012). Nevertheless, since JCV T-ag is
known to accumulate in the nuclei of glial cells derived from PML
patients (Stoner et al., 1986), it is concluded that Hs 683 and U87
cells are not ideal models for additional studies of this disease.
That the C33A based JCV DNA replication assay will be used for
many additional studies is suggested by its cost-effectiveness,
speed at which replication experiments can be performed and
the high-throughput format of the reactions. Indeed, our studies
with known DNA replication inhibitors establish that it is an
excellent assay for subsequent screening for additional inhibitors
of JCV DNA replication. The C33A based JCV DNA replication assay
will also be useful for further reﬁning our understanding of the
protein/DNA interactions that regulate JCV DNA replication. It will
also serve as a very valuable control during subsequent studies
designed to detect JCV DNA replication in glial cells. Finally, given
that JCV DNA is efﬁciently replicated in C33A cells, it is likely that




The construction of a plasmid encoding full-length JCV T-ag,
that was termed pCMV-JCVT-ag, was previously described (Meinke
et al., 2014). A plasmid containing the JCV origin of replication was
obtained from Dr. H.P. Nasheuer. The origin regions present in this
construct include Site II, Site I and one copy of the 98 bp enhancer
sequence present in the Mad-1 strain of JCV (Frisque, 1983; Frisque
et al., 1984). This origin containing fragment was obtained by PCR
and then subcloned, via Gibson Assembly (New England Biolabs),
into plasmid pFL (Fradet-Turcotte et al., 2010) at the Dra III site;
the resulting plasmid was termed pFL-JCVori. Subsequent dele-
tions of the 98 bp enhancer and Site I regions were generated
using the QuikChange II kit (Agilent Technologies). Additional
Gibson Assembly reactions were used to insert a second copy of
the enhancer into pFL-JCVori, this re-created the tandem
duplication found in the Mad-1 strain (Frisque et al., 1984). The
resulting tandem duplication containing plasmid was termed
pFL-JCVori-TD.
Point mutations at selected residues were introduced into
pCMV-JCVT-ag using the QuikChange II kit (Agilent Technologies).
The oligonucleotides used in these procedures are as follows (the
complements to the individual oligonucleotides are not listed): for





and for H514A (50 GTGTGAAAGTTAATTTAGAGAGAAAAGCCCAAAA-
CAAAAGAACACAGGTGTTTC-30). The bases that were inserted in
order to introduce the indicated alanines are underlined. Additional
QuikChange reactions were used to generate the mutation of
the NF-1A binding sites within the enhancer. The oligonucleotide
used to mutate the NF-1A binding site (Amemiya et al., 1992) was
50–CCCTAGGTATGAGCTCATGCTCAGCTGGCAGTAATCCCTTCCC-3 (the
complement is not listed); the mutated bases in the NF1 binding
site are underlined (Ravichandran et al., 2006). Finally, DNA
sequencing at the Tufts University Core Facility was used to verify
the DNA sequences present in all plasmid constructs.
Fig. 9. Determining whether all four pentanucleotides in the Site II region of the core origin are required for JCV replication. A. Sequences of the JCV core origin, including the
four pentanucleotides in the Site II regions. The transition mutations that are substituted for the individual pentanucleotides (P1-P4) are shaded in gray. B. Results of JCV
replication assays conducted with the pFL-JCVori derivatives containing transition mutations of the individual pentanucleotides. As a negative control, a reaction was conducted
with a plasmid lacking an origin (i.e., pFL; far left column). As a positive control, an additional reaction was conducted with plasmid pFL-JCVori (second column from the left).
The levels of replication obtained with the plasmids containing the transition mutations in the individual pentanucleotides are shown in the following four columns.
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Cell culture and transfections
The C33A cervical carcinoma cell line was grown in EMEM
medium (ATCC) supplemented with 10% FBS (Atlanta Biologicals)
in 5% CO2. The Hs 683 cells (ATCC) were grown in DMEM
supplemented with 15% FBS. The U87 cells were grown in EMEM
supplemented with 10% FBS. Transfections of cells were conducted
in bulk using the Lipofectamine 2000 reagent (Invitrogen) accord-
ing to the manufacturer's recommendation.
JCV replication assays
As with our previously described SV40 and HPV31 assays
(Fradet-Turcotte et al., 2010), the JCV replication assay requires
several plasmids. One contains the ﬁreﬂy luciferase gene, either in
the presence of the JCV origin (e.g., pFL-JCVori), or in its absence
(pFL). The reactions also require a plasmid encoding JCV T-ag (e.g.,
pCMV-JCVT-ag or, alternatively, mutant forms of pCMV-JCVT-ag).
Moreover, as a transfection control, all reactions contained 0.5 ng
of the Renilla luciferase (Rluc) containing plasmid pRL. Finally, the
total amount of plasmid transfected was adjusted to 100 ng with
plasmid pCI ((Fradet-Turcotte et al., 2010); used as an empty
vector control). Following transfection for 4-h, with the requisite
plasmids in the absence of serum, FBS was added (10% for C33A
and U87 cells, 15% for Hs 683 cells). The transfected C33A cells
were then plated in white ﬂat-bottom 96-well plates (costar
♯3917) at a density of 25,000 cells/well. Fireﬂy and Renilla
luciferase activities were measured at the indicated times using
a Dual-Glo Luciferase assay system (Promega).
Western blots
JCV large T-ag was detected using the Pab 416 antibody (Santa
Cruz Biotechnology). As a loading control, vinculin levels were
determined using the HVIN-1 monoclonal Ab (Sigma). To conduct
the actual Western blots, proteins were transferred to a PVDF
membrane (Millipore). After addition of the appropriate primary
antibody, the protein bands were detected using a horseradish
peroxidase-conjugated rat anti-mouse secondary antibody (BD
Pharmingen) and enhanced chemiluminescence detection kit
(Millipore).
qPCR
Six well plates containing C33A cells (3105) were trans-
fected with 50 ng of pFL-JCVori and 400 ng of pCMV-JCVT-ag.
To standardize the reactions, the Renilla encoding plasmid was
added (10 ng) and the total amount of plasmid DNA was adjusted
to 2 μg with pCI. Total genomic DNA was extracted 48 h. post-
transfection using the DNeasy Blood and Tissue Kit from Qiagen.
To measure the amount of replicated pFL-JCVori plasmid, an
aliquot of the genomic DNA (25 μl) was digested with 10 units of
Dpn I for 16 h, followed by digestion with exo III (100 units) for
30 min.. The primers used to amplify an 80 bp region of the ﬁreﬂy
luciferase gene were 50–TCCTTCGATAGGGACAAGACAATT-30 and
50–GGCAGAGCGACACCTTTAGG-30. The site-speciﬁc probe used in
these assays, derived from the luciferase gene, was 50-/56-FAM/
CACTGATCA/ZEN/TGAACTCCTCTGGATCTACTGGTC/3IABkFQ/-3'. All
samples were run in triplicate using the TaqMan PerfeCTa qPCR
ToughMix UNG ROX (Quanta).
Immunoﬂuorescence
The “standard” immunoﬂuorescence microscopy assays were
conducted as previously described (Boichuk et al., 2010). After
seeding, cells (2105) were allowed to attach to poly-L-Lysine-
coated glass coverslips for approximately 24 h.. Using the Lipofec-
tamine 2000 reagent, the cells were then transfected with the
desired plasmids (2 μg total of DNA). After the addition of serum,
the cells were incubated at 37 1C for an additional 48 h. Cells were
then washed with phosphate-buffered saline (PBS) and then ﬁxed
in 4% paraformaldehyde in PBS for 15 min. The cells were then
washed twice with PBS and permeabilized via the addition of 0.2%
Triton X-100, dissolved in PBS, for 5 min.. The cells were washed
again three times with PBS. To block nonspeciﬁc binding the cells
were then incubated with 10% goat serum (Invitrogen) for 20 min.
Fig. 10. Evidence that the C33A based JCV DNA replication assay can be used to test
inhibitors of JCV DNA replication. JCV DNA replication assays were conducted with
the indicated amounts of the replication inhibitors aphidicolin, hydroxyurea and
gemcitabine. The EC50 values are indicated.
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The permeabilized cells were then treated with a 1/1000-fold
dilution of the Pab 416 anti T-ag monoclonal Ab (Santa Cruz
Biotechnology) for 1 h, followed by three washes with PBS. The
secondary goat anti-mouse antibody, conjugated with Alexa 488
(Life technologies) was diluted 1/1000 and applied for 1 h.. After
three additional washes with PBS, the cells were stained brieﬂy
with DAPI (40, 60-diamidino-2-phenylindole) and covered with
cover slips coated with “mounting medium” (Electron Microscopy
Sciences). The cells were then visualized using a Zeiss Axiovert
200 M microscope employing the 63X objective. The OpenLab
software package (Perkin-Elmer) was used to acquire and process
images. A variation of this protocol involved “pre-extraction“ of
unbound T-ag (Mirzoeva and Petrini, 2001). Cells were initially
pre-extracted with CSK buffer (10 mM PIPES, pH 7, 100 mM NaCl,
300 mM sucrose, 3 mMMgCl2, 1 mM EGTA and 0.5% Triton X-100);
the remaining steps are identical to the “Standard method”.
Molecular modeling
The molecular graphics images were generated using the
program PyMOL (DeLano, 2002). The structures used in the
molecular modeling discussed herein are the apo JCV T-ag OBD
(RCSB PDB code 4LMD) and the JCV helicase domain threaded onto
the SV40 T-ag helicase domain (PDB code 1SVM) using the
program Phyre2 (Kelley and Sternberg, 2009).
Inhibitor testing
Approximately 25,000 C33A cells were seeded in a 96-well
plate and co-transfected the day after with 20 ng of pCMV-JCVT-
ag, 2.5 ng pFL-JCVori, 0.5 ng of pRL and 77 ng of carrier DNA (pCI).
The culture medium was replaced 4 h post-transfection with fresh
medium containing the inhibitor or with vehicle alone (0.1%
DMSO) as a control. Cells were then incubated for 24 h and the
culture medium replaced with fresh medium lacking inhibitor
prior to measuring the levels of ﬁreﬂy and Renilla luciferase using
the Dual-Glo Luciferase assay system (Promega). Inhibitors were
tested in duplicate 12-point dose response curves, in two inde-
pendent experiments. Dose response curves were generated by
two-fold serial dilution of each compound starting at a maximal
concentration of 10 mM for aphidicolin, 10 mM for hydroxyurea
and 2 mM for gemcitabine. EC50 values were calculated with
the GraphPad Prism 6 software by ﬁtting the data to the
following equation: % DNA replication¼Lowþ(100Low)/
(1þ10^((LogEC50[I])n)), in which Low represents the lowest
percentage of DNA replication reached at saturating amounts of
inhibitor, [I] is the concentration of the inhibitor (M), and n is the
Hill coefﬁcient.
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